基本情報
研究キーワード
18経歴
3-
2017年4月 - 現在
-
2013年4月 - 2017年3月
-
2005年4月 - 2013年4月
学歴
3-
2000年4月 - 2005年3月
-
1991年4月 - 1995年3月
-
1989年4月 - 1991年3月
論文
143-
IJC Heart & Vasculature 54 101507-101507 2024年10月
-
Hypertension research : official journal of the Japanese Society of Hypertension 2024年9月19日The Japanese Society of Hypertension have established a blood pressure (BP) target of 130/80 mmHg for patients with coronary artery disease (CAD). We evaluated the data of 8793 CAD patients in the Clinical Deep Data Accumulation System database who underwent cardiac catheterization at six university hospitals and the National Cerebral and Cardiovascular Center (average age 70 ± 11 years, 78% male, 43% with acute coronary syndrome [ACS]). Patients were divided into two groups based on whether or not they achieved the guideline-recommended BP of <130/80 mmHg. We analyzed the relationship between BP classification and major adverse cardiac and cerebral event (MACCE) separately in two groups: those with ACS and those with chronic coronary syndrome (CCS). During an average follow-up period of 33 months, 710 MACCEs occurred. A BP below 130/80 mmHg was associated with fewer MACCEs in both the overall (hazard ratio [HR] 0.83, 95% confidence interval [CI] 0.70-1.00, p = 0.048) and the ACS group (HR 0.67, 95%CI 0.51-0.88, p = 0.003). In particular, stroke events were also lower among those with a BP below 130/80 mmHg in both the overall (HR 0.69, 95%CI 0.53-0.90, p = 0.006) and ACS groups (HR 0.44, 95%CI 0.30-0.67, p < 0.001). In conclusion, the achievement of BP guidelines was associated with improved outcomes in CAD patients, particularly in reducing stroke risk among those with ACS.
-
International Journal of Cardiology: Cardiovascular Risk and Prevention 22 2024年9月The authors regret that the original version of the article incorrectly stated the study period as “April 2014 to March 2020" in both the Abstract and the Methods section. The correct study period should have been “April 2013 to March 2019". The authors would like to apologise for any inconvenience caused.
-
IJC Heart & Vasculature 101430-101430 2024年5月
-
日本循環器学会学術集会抄録集 88回 OE42-4 2024年3月
MISC
68-
International Heart J 49(3) 313-327 2008年
-
AMERICAN JOURNAL OF CARDIOLOGY 100(12) 1750-1753 2007年12月Statins and renin-angiotensin system (RAS) inhibitors are 2 classes of drugs prescribed frequently in clinical practice that may have pleiotropic effects in addition to cholesterollowering and blood pressure-lowering effects, respectively. Combined treatment with statins and RAS inhibitors may have additional benefits beyond each monotherapy. We assessed the usefulness of the combined treatment in the Japanese Coronary Artery Disease (JCAD) Study population. In the JCAD Study, 13,812 patients with angiographically shown narrowing in >= l of 3 major coronary arteries were followed up for a mean of 2.7 years. The primary end point of the study was all cardiovascular events. In the present study, baseline covariates possibly influencing the event rate were adjusted between the control and treatment groups. Although there were no statistically significant differences in event rates between patients receiving neither statins nor RAS inhibitors and those receiving either drug, Kaplan-Meier analysis showed a 22% decrease (p = 0.0286) in the event rate with combined treatment. In conclusion, statins combined with RAS inhibitors may decrease cardiovascular events in patients with coronary artery disease. (C) 2007 Elsevier Inc. All rights reserved.
-
Circulation journal : official journal of the Japanese Circulation Society 71 307-307 2007年3月1日
-
Circulation journal : official journal of the Japanese Circulation Society 71 44-44 2007年3月1日
-
Circulation J 71(12) 1835-1840 2007年
-
Circulation journal : official journal of the Japanese Circulation Society 70 609-609 2006年3月1日
-
CIRCULATION 112(17) U518-U518 2005年10月
-
Arterioscler Thromb Vasc Biol. 25 155-160 2005年
-
社会技術研究論文集 3 196-204 2005年Our group of medical safety, mission program 1 in Shakai-Gijutsu, has been making inter-disciplinary researches for improvement of medical safety. We has developed "Clinical Navigation System", which will be taken advantage of as tools for communication of clinical knowledge, between patients & medical doctors, between medical doctors & medical doctors, and between clinics & hospitals.
-
ATHEROSCLEROSIS SUPPLEMENTS 4(2) 60-60 2003年9月
-
ATHEROSCLEROSIS SUPPLEMENTS 4(2) 214-214 2003年9月
-
Japanese circulation journal 64(10) 750-754 2000年
共同研究・競争的資金等の研究課題
4-
日本学術振興会 科学研究費助成事業 2014年4月 - 2017年3月
-
日本学術振興会 科学研究費助成事業 2011年4月 - 2014年3月
-
日本学術振興会 科学研究費助成事業 2010年 - 2012年
-
日本学術振興会 科学研究費助成事業 2005年 - 2006年